By: J.S.,STA
Drug company Krka, which has significant exposure to the Russian and Ukrainian markets, said it could not yet assess the impact of the current situation in the two countries on its operations in 2022.
But it stressed it had a strong capital structure, robust money flow and no financial debt, so long-term operations were not at risk. Sales revenue in the first quarter of 2022 has been estimated at EUR 25.9 million, up from EUR 22 million in the same period last year. Krka said all activities in Russia were running without major disruption except for delays in transport.